EU Pharma Package 2026: What Market Access
Teams Should
Prepare for Before Formal Adoption
Europe is approaching the most significant reform of its pharmaceutical legislation in more than two decades.
Following the political agreement reached by the European Parliament and the Council in December 2025, the compromise texts for the revised EU pharmaceutical framework were published in March 2026. The legislation is now moving through the remaining legal and linguistic procedures required before formal adoption and publication in the Official Journal of the European Union.
The precise adoption date has not yet been officially confirmed. However, legal and policy analysis indicates that formal approval could take place during autumn 2026.
For pharmaceutical companies, this is no longer a distant policy discussion.
The EU Pharma Package could influence regulatory data protection, market exclusivity, medicine availability, generic and biosimilar competition, antimicrobial development and the sequencing of European product launches.
Its effects will extend beyond Regulatory Affairs and Legal departments. Market Access, Health Economics and Outcomes Research, Real-World Evidence, Medical Affairs, Pricing and Commercial teams will all need to understand how the new framework could change evidence planning and patient-access strategy.
The critical question is no longer whether Europe’s pharmaceutical legislation will change. It is whether companies are prepared to operate under the new framework.
Where Does the EU Pharma Package Stand?
The European Commission originally proposed the reform in April 2023. Its purpose was to modernise pharmaceutical legislation that had remained largely unchanged for approximately 20 years.
The proposed package consists of a new directive and regulation governing medicinal products for human use and the operation of the European Medicines Agency.
Following negotiations between the European Parliament, the Council and the European Commission, a political agreement was reached in December 2025. Compromise texts reflecting that agreement were subsequently published in March 2026.
According to the European Medicines Agency, the adopted legislation is expected to enter into force in 2026. This will be followed by a transition period during which Member States, the European Commission, EMA and national authorities will prepare for implementation.
The new framework is expected to become fully applicable after the transition period, currently anticipated for 2028.
Before this can happen, the European Parliament and the Council must formally approve the texts. The legislation must then be published in the Official Journal of the European Union.
Because the exact adoption date remains subject to the EU legislative process, companies should treat autumn 2026 as an important monitoring period, not as a guaranteed implementation deadline.
The EU Pharma Package is often presented as a regulatory reform, but many of its most important consequences will affect market access.
Regulatory approval establishes whether a medicine can be marketed. It does not determine:
- Whether the medicine will be reimbursed
- Which patients will be eligible
- Whether the price will be accepted
- Whether the product is considered cost-effective
- How it will be positioned in national treatment pathways
- How quickly patients will receive access
- Whether national authorities will require additional evidence
The revised pharmaceutical framework will also operate alongside the EU Health Technology Assessment Regulation.
For eligible products, the Joint Clinical Assessment provides a common European assessment of relative clinical effectiveness and safety. Pricing, reimbursement, economic evaluation and final access decisions nevertheless remain national responsibilities.
Pharmaceutical companies must therefore prepare for an interconnected system involving:
- EMA regulatory assessment
- EU-level Joint Clinical Assessment
- National HTA
- Pricing and reimbursement
- Supply obligations
- Exclusivity and competition
- Post-launch evidence generation
The organisations best prepared for the new environment will not manage these requirements as isolated processes.
1. Regulatory Data Protection and Market Protection
One of the most closely watched elements of the reform is the future of regulatory data and market protection.
Under the political agreement, new medicines are expected to receive eight years of regulatory data protection and one year of market protection. An additional period of protection may be available when a product meets defined innovation-related conditions.
Regulatory data protection prevents another applicant from relying on the originator’s preclinical and clinical data when applying for approval during the protected period. Market protection prevents a generic or biosimilar product from being placed on the market during the applicable period.
The final framework matters because exclusivity influences:
- Product lifecycle planning
- Revenue forecasts
- Investment decisions
- Indication-extension strategy
- Generic and biosimilar entry
- Launch sequencing
- Commercial sustainability
Market Access and Commercial teams should model multiple exclusivity scenarios rather than waiting for the final legislation to enter into force.
For pipeline assets, companies should examine whether development decisions, additional indications or innovation criteria could influence the available protection period.
2. European Launch Sequencing Could Become More Complex
The reform seeks to improve the availability of medicines across the European Union. However, product availability is shaped by more than marketing authorisation.
After regulatory approval, companies must still navigate different national HTA, pricing and reimbursement systems. These processes vary considerably in their evidence requirements, timelines, negotiation structures and willingness to pay.
Manufacturers must consider:
- Which countries should be prioritised
- When national submissions should begin
- Whether launch order creates international reference-pricing exposure
- How JCA findings will be used nationally
- Which evidence gaps could delay reimbursement
- Whether supply can be maintained across target markets
- How lower prices in one country could affect negotiations elsewhere
These decisions will become increasingly interconnected.
A European launch strategy based only on regulatory timing may fail to account for JCA readiness, national payer expectations, international reference pricing and supply responsibilities.
Companies should therefore establish an integrated launch-sequencing process involving Regulatory, Market Access, Pricing, Supply, Legal and Commercial teams.
3. Medicine Supply Will Become a Strategic Access Issue
The revised framework places greater attention on medicine availability and supply security.
The political agreement includes provisions enabling Member States to require marketing-authorisation holders to maintain sufficient and appropriate supplies of medicines.
This reflects growing concern about shortages, supply-chain vulnerability and unequal medicine availability across Europe.
Supply planning should no longer be treated solely as an operational matter. It can influence:
- Market-entry commitments
- Procurement eligibility
- Payer confidence
- Hospital access
- Contracting strategy
- Reputation with authorities and patients
- The feasibility of launching in multiple countries
Market Access teams should understand whether reimbursement commitments can be supported by manufacturing and distribution capacity.
Before launching in a new market, companies may need to demonstrate that they can maintain reliable supply under different demand, procurement and pricing scenarios.
4. Generic and Biosimilar Competition May Accelerate
The political agreement also clarifies the exemption allowing generic and biosimilar manufacturers to complete certain preparatory activities before the originator product’s patent or supplementary protection certificate expires.
These activities may include studies, regulatory submissions, HTA-related preparation, pricing and reimbursement procedures, and participation in procurement processes where permitted by the final legislation.
The objective is to allow competitors to enter the market more quickly after the applicable protection expires.
For originator companies, this makes lifecycle planning more important. Teams should assess:
- Expected loss-of-exclusivity timing
- Competitor development activity
- Biosimilar or generic filing strategies
- Tender exposure
- Indication-level differentiation
- Evidence supporting continued value
- Contracting and pricing options
- Post-launch RWE requirements
Generic and biosimilar companies, meanwhile, may gain more opportunity to prepare regulatory and access pathways before commercial entry becomes legally possible.
5. A New Incentive for Priority Antimicrobials
The reform includes a proposed transferable exclusivity voucher intended to encourage the development of priority antimicrobials.
Under the political agreement, an eligible antimicrobial developer could receive an additional period of market protection that may be transferred to another qualifying product. Restrictions are expected to apply, including limitations connected with the sales value of the product receiving the extension.
The mechanism attempts to address a longstanding problem: society urgently needs new antibiotics, but the traditional commercial model often provides insufficient returns to support development.
The voucher could encourage investment, but it also raises important questions:
- Which antimicrobials will qualify?
- How will eligibility be assessed?
- What will a voucher be worth?
- Which products could receive an extension?
- How might delayed competition affect healthcare expenditure?
- Will the incentive generate meaningful antimicrobial innovation?
- How will payers respond to extended market protection?
Market Access teams working with infectious-disease portfolios should monitor the final eligibility, transfer and implementation rules carefully.
6. Orphan and Paediatric Development Will Require Reassessment
The EU pharmaceutical reform also revises aspects of the incentive framework for orphan and paediatric medicines.
Rare-disease development presents distinctive evidence and access challenges:
- Small patient populations
- Limited comparator evidence
- Single-arm trials
- Uncertain long-term outcomes
- Reliance on indirect comparisons
- Difficulties generating country-specific epidemiology
- High budget impact per eligible patient
- Substantial post-launch evidence requirements
These challenges are also relevant to EU HTA. Orphan medicines are scheduled to enter the mandatory JCA framework from January 2028.
This means companies developing rare-disease products must prepare for two major transitions: revised pharmaceutical legislation and the expansion of Joint Clinical Assessment.
Evidence plans should connect regulatory incentives with:
- PICO forecasting
- External comparator strategy
- Natural-history evidence
- Patient registries
- Patient-reported outcomes
- Indirect treatment comparisons
- National epidemiology
- Post-authorisation RWE
- Managed-entry agreements
Waiting until the product approaches submission may leave insufficient time to address these requirements.
7. The EU Pharma Package and EU HTA Must Be Planned Together
The pharmaceutical legislation and the EU HTA Regulation have different legal purposes.
EMA assesses a medicine’s quality, safety and efficacy. Joint Clinical Assessment examines its relative clinical effectiveness and safety against relevant alternatives. National authorities then determine price, reimbursement, cost-effectiveness and local positioning.
Despite these distinctions, the evidence requirements are connected.
A pivotal trial designed primarily for regulatory approval may not address all comparators, subgroups or outcomes requested through the consolidated JCA PICO scope.
Similarly, a JCA report may describe the relative clinical evidence without resolving national questions concerning:
- Cost-effectiveness
- Budget impact
- Local epidemiology
- Affordability
- Treatment positioning
- Reimbursement restrictions
- Implementation costs
- Outcomes-based agreements
The new pharmaceutical framework adds further considerations involving exclusivity, availability, supply and competition.
Companies therefore need one integrated European evidence and access strategy—not separate regulatory, JCA and national Market Access plans.
What Should Companies Do Before Formal Adoption?
Pharmaceutical organisations do not need to wait for the final publication before beginning readiness work.
Review pipeline exposure
Identify which marketed and pipeline products could be affected by revised protection periods, supply provisions, competition rules, orphan incentives or antimicrobial measures.
Model different exclusivity scenarios
Evaluate how the final protection framework could affect revenue, indication strategy, lifecycle investment and anticipated generic or biosimilar entry.
Stress-test European launch sequencing
Assess how EU HTA timelines, national reimbursement processes, international reference pricing, availability expectations and supply capacity interact.
Connect regulatory and Market Access planning
Ensure Regulatory, Clinical, HEOR, RWE, Pricing, Supply, Legal and Commercial teams work from a shared development and launch roadmap.
Strengthen PICO forecasting
Identify likely populations, comparators and outcomes before pivotal evidence plans are locked.
Prepare national evidence requirements early
JCA will not replace country-specific economic evaluation, budget-impact analysis, epidemiology or payer negotiation.
Evaluate supply readiness
Determine whether manufacturing and distribution plans can support market-entry and availability commitments across different Member States.
Monitor implementation guidance
The legislation itself will not answer every operational question. EMA, the European Commission and national authorities are expected to issue implementing measures, delegated acts and stakeholder guidance during the transition.
The Next Phase Will Be Implementation
Formal adoption will be a major milestone, but it will not be the end of the reform process.
Once the legislation enters into force, attention will shift towards:
- Implementing and delegated acts
- EMA guidance
- National legislative changes
- Transitional arrangements
- Updated regulatory procedures
- New IT and submission requirements
- Industry interpretation
- Operational readiness
The greatest risk for pharmaceutical companies is not simply misunderstanding one provision. It is failing to recognise how the new legislation interacts with EU HTA, national reimbursement, product protection, supply and commercial strategy.
The companies best positioned for the transition will be those that begin cross-functional preparation before every technical detail is finalised.
Continue the Discussion in Amsterdam
The implications of the EU Pharma Package, Joint Clinical Assessment, PICO strategy, Real-World Evidence, pricing and national Market Access will be highly relevant to the discussions taking place at the European RWE & Market Access Summit 2026 – JCA & PICO Strategy Edition.
The summit will bring together senior leaders from Pharma, Market Access, HEOR, RWE, Medical Affairs, Pricing and Reimbursement, HTA and evidence-generation organisations on 21–22 October 2026 at Inntel Hotels Amsterdam Landmark.
As Europe moves from policy design to implementation, the summit provides a timely opportunity to examine how pharmaceutical companies can align evidence, regulatory and access strategies in the new European environment.